Leadership, Scientific Vision & Long-Term Commitment
Branca Bunús was built on the dual strength of world-leading biomaterials scientific invention and experienced global biotech entrepreneurial leadership, united around a shared mission to translate HPAE platform innovation into patient-focused genetic medicines.
Founding complementary leadership
Strategic partnership
Branca Bunús Ltd and PolyGene Biotech operate as independent entities under a long-term strategic partnership, founded by the HPAE technology inventor Professor Wenxin Wang. BrB retains the ownership of HPAE platform intellectual property and leads therapeutic pipeline development; PolyGene holds exclusive global manufacturing, distribution and commercialisation rights for all transfection reagent lines.
Professor Wenxin Wang
Founder & Chief Scientific Officer
- Inventor of the proprietary HPAE hyperbranched polymer gene delivery platform
- Chair Professor, University College Dublin Charles Institute of Dermatology
- Serial biotech founder (Vornia Biomaterials, successfully acquired)
- Globally recognised authority in biodegradable biomaterials research
“Scientific discovery creates possibility. Our responsibility is to translate that possibility into technologies that improve patients’ lives.”
Dr Hongyun Tai
Co-Founder & Chief Executive Officer
- Polymer scientist and cross-border biotech entrepreneur
- Oversees global corporate strategy, international partnerships and commercial translation roadmaps
- Leads BrB’s positioning as a globally competitive platform biotechnology enterprise
“Innovation creates its greatest impact when science, entrepreneurship and collaboration advance together.”
A cross-disciplinary scientific team
Our team combines polymer chemists, cell biologists, regulatory specialists and corporate business professionals, unified around the shared goal of advancing the HPAE platform and novel genetic therapies.
Scientific Excellence
Pursue rigorous, peer-reviewed research and continuous polymer innovation.
Translation Focus
Prioritise research that delivers tangible real-world patient and lab benefits.
Collaborative Mindset
Build long-term, transparent academic and industry partnerships.
Full Integrity
Operate with complete transparency in science, regulatory and commercial activity.
Long-Term Vision
Invest in scalable platform technology rather than short-term narrow product gains.
Key corporate milestones
2019
Company founded
Branca Bunús founded as a UCD spin-out High Potential Start-Up company.
Ongoing
UCD academic research partnership
Core academic research partnership established and continuously extended.
Quality
ISO 9001 certification
Full ISO 9001 quality management system certification achieved.
Regulatory
FDA Type II DMF
Filing completed for the lead transfection reagent product.
Therapeutics
EMA Orphan Drug Designations
Granted for the BRB101 and BRB202 rare disease programmes.
2026
PolyGene partnership
Strategic global commercial partnership established with PolyGene Biotech.
Global scientific knowledge sharing
Our core team regularly delivers invited conference lectures, hosts academic collaborative workshops and participates in global cell and gene therapy societies including ASGCT, ESGCT, ISCT, ISGCT, CSGCT and EB international research meetings to advance shared industry knowledge.
Our long-term corporate objective is to establish Branca Bunús as a globally recognised leader in non-viral gene delivery platform innovation. All scientific, commercial and collaborative decisions remain anchored to our founding mission of developing safer, more accessible genetic medicines for patients worldwide.